fluphenazine has been researched along with lidocaine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Brouillette, WJ; Brown, GB; Zha, C | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Peris, J; Zahniser, NR | 1 |
| Bloch, RJ | 1 |
| Campos, E; Chayet, L; Collados, L; García, L; Kettlun, AM; Traverso-Cori, A; Valenzuela, MA | 1 |
| Desai, KP; Desai, PM | 1 |
| Chow, JC; Christ, WJ; Daun, JM; Gusovsky, F; Rose, JR; Yang, H | 1 |
| Brager, AJ; Glass, JD; Prosser, RA; Stowie, AC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
2 review(s) available for fluphenazine and lidocaine
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for fluphenazine and lidocaine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
Topics: Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Voltage-Gated Sodium Channels | 2014 |
Persistent augmented dopamine release after acute cocaine requires dopamine receptor activation.
Topics: Animals; Apomorphine; Benzazepines; Cocaine; Dopamine; Dopamine Antagonists; Fluphenazine; Lidocaine; Male; Mazindol; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sulpiride | 1989 |
Loss of acetylcholine receptor clusters induced by treatment of cultured rat myotubes with carbachol.
Topics: Animals; Calcium; Carbachol; Chlorides; Dose-Response Relationship, Drug; Fluphenazine; Lidocaine; Muscles; Potassium; Proadifen; Protease Inhibitors; Protein Conformation; Rats; Receptors, Cholinergic; Sodium | 1986 |
Human placental ecto-enzymes: studies on the plasma membrane anchorage and effect of inhibitors of ATP-metabolizing enzymes.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Amitriptyline; Apyrase; Caffeine; Cell Membrane; Endopeptidases; Enzyme Inhibitors; Female; Fluphenazine; Glycosylphosphatidylinositols; Humans; Lidocaine; Microvilli; Nucleotides; Phosphatidylinositol Diacylglycerol-Lyase; Phospholipase D; Placenta; Type C Phospholipases | 1997 |
Combined fluphenazine and lidocaine for pain relief in head and neck cancers.
Topics: Anesthetics, Local; Dopamine Antagonists; Drug Therapy, Combination; Female; Fluphenazine; Head and Neck Neoplasms; Humans; Injections, Intralesional; Lidocaine; Male; Nerve Block; Pain Measurement; Pain, Intractable; Treatment Outcome | 2000 |
Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.
Topics: Adolescent; Adult; Cell Line; Chlorpromazine; Female; Fluphenazine; Humans; In Vitro Techniques; Interleukin-6; Leukocytes, Mononuclear; Lidocaine; Lipid A; Lipopolysaccharides; Male; Middle Aged; Rhodobacter sphaeroides; Trifluoperazine | 2000 |
Cocaine modulates pathways for photic and nonphotic entrainment of the mammalian SCN circadian clock.
Topics: Animals; Circadian Clocks; Cocaine; Dopamine Uptake Inhibitors; Fluphenazine; Lidocaine; Male; Metergoline; Mice; Mice, Inbred C57BL; Models, Animal; Motor Activity; Photic Stimulation; Serotonin Receptor Agonists; Signal Transduction; Suprachiasmatic Nucleus | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |